Management of dyslipidaemia

Heart

Volumn 90, Issue 8, 2004, Pages 949-955

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE DERIVATIVE; ANTIOXIDANT; ATORVASTATIN; COLESTYRAMINE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LINOLENIC ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROL; VITAMIN;

CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DYSLIPIDEMIA; EUROPE; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNITED KINGDOM; UNITED STATES;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; PRACTICE GUIDELINES;

EID: 3442895390     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.021287     Document Type: Review

References (22)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomised controlled trials. JAMA 1999;282:2340-6. Meta-analysis of 20th century triols showing the magnitude of the reduction by first generation statins of coronary heart disease events.
2. Crause JR III, Byington RP, Hoen HM, et al. Reductase inhibitor montherapy and stroke prevention. Arch Int Med 1997;157:1305-10. Metaanalysis which showed a significant reduction in cerebrovascular events by statins in secondary but not primary prevention trials.
3. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-29.
4. Department of Health. The National Service Framework for coronary heart disease. London: Department of Health, 2000.
5. Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. Executive summary of the Third Repart of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97. Current US guidelines which advocate the use of plant sterols and stanols in the dietary management of dyslipidaemia, the first to do so.
6. De Backer G, Abrosioni E, Borch-Johnsen K, et al. Executive summary: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10. Very recently published European guidelines on the prevention of cardiovascular disease, including a new method of calculating risk.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. Ground breaking trial which demonstrated that treatment with simvastatin 40 mg daily reduced risk of coronary events and strokes in high risk subjects, irrespective of their age and cholesterol level.
8. Miettinen TA, Puska P, Gylling H, et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesteromeic population. N Engl J Med 1995;333:1308-12. Finnish study showing for the first time that the cholesterol lowering effects of plant stanol ester were maintained over the course of a year.
9. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861-4.
10. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Arterioscler Thromb Vasc Biol 2000;20:1340-6. Subgroup analysis of the 4S triol which identified poor responders to statins as being high absorbers and law synthesisers of cholesterol.
11. Blair SN, Capuzzi DM, Gottlieb SO, et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86:46-52.
12. Bucher HC, Hengstler P, Schindler C, et al. n-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomised controlled trials. Am J Med 2002;112:298-304. Important meta-analysis of trials showing the beneficial effects af consumption of ω3 fatty acids as fish or fish oil, especially in preventing sudden death.
13. Leaf A, Kang JX. Dietary n-3 fatty acids in the prevention of lethal cardiac arrhythmias. Curr Op Lipidol 1997;8:4-6.
14. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60. Open label, parallel groups study showing greater LDL lowering efficacy of rosuvastatin compared with other statins over its dose range of 10-40 mg daily.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2002;288:2998-3007.
16. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA 2004;291:1132-4.
17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
18. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363-8.
19. Thompson GR. Combination therapy with statins. In: Gaw A, Packard CJ, Shepherd J, eds. Statins: the HMG CoA reductase inhibitors in perspective, 2nd ed. Martin Dunitz. 2004:189-99.
20. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34. Study showing additive effects of ezetimibe 10 mg daily in lowering LDL over a wide range of doses of simvastatin.
21. Gagne C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75.
22. De Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7.